Bayer AG PK (BAYRY)

12.93
-0.45(-3.36%)
Pre Market
12.85
-0.08(-0.62%)
- Delayed Data
  • Volume:
    686,507
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    12.90 - 13.04

BAYRY Overview

Prev. Close
13.39
Day's Range
12.9-13.04
Revenue
48.62B
Open
12.99
52 wk Range
12.9-17.34
EPS
0.06
Volume
686,507
Market Cap
50.29B
Dividend (Yield)
0.58
(4.67%)
Average Vol. (3m)
496,410
P/E Ratio
199.06
Beta
1.18
1-Year Change
-12.99%
Shares Outstanding
982,424,082
Next Earnings Date
Mar 01, 2022
What is your sentiment on Bayer AG PK?
or
Market is currently closed. Voting is open during market hours.

Bayer AG PK Company Profile

Employees
99814

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell
  • get rid of roundup, pay off lawsuits, and kick the ceo to the curb
    0
    • Need to buy on this dip..
      0
      • If next year earns more than 2 USD EPS, this company will have a value among 36 USD 40 USD. Have a nice day!
        0
        • Whats up? Nobody is gona talk about bayer?
          0
          • bayer is gonna lose and invoke higher payouts to plaintiffs with current results..dump this now
            4
            • so far $25 billion settlement minimum by the LA times article and St. Louis article puts it at $30 billion..its heating up fast guys..hold on to your seats. i expect 25 share price the be the norm.
              3
              • 30 next year
                0
                • bayer settlement at 50 billion possible?
                  1
                  • Where did you read that?
                    2
                  • Seeing bayer sell not one but 3 sub-division companies for estimated $8-10 billion each... delaying 2 different cases involving two 15 year olds from roundup and the plaintiffs lawyers is a big shot that can get money from bayer..this is going down past 15 short term...oh and 70,000 cases verified now..so im guessing the settlement of the century is upon us..about $40-50 billion seems right in the alley.
                    1
                • 27 usd up
                  1
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.